MET 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
This Target Evaluation Report for MET is generated from PatSnap Life Sciences MCP data workflows, combining Target & Disease MCP biology context with Clinical Trials MCP validation and competitive signals.
For AI teams building biomedical agents, PatSnap Life Sciences MCP Servers provide structured retrieval across target biology, disease context, clinical trials, drug evidence, IP intelligence, and other R&D intelligence sources.
382 Direct drug records from Target & Disease MCP | 271 Development records in target context | 458 Disease associations captured | 1276 Clinical trial records from Clinical Trials MCP |
Explore PatSnap Life Sciences MCP Servers for AI agents
Executive View
c-Met links growth-factor signaling to invasion, survival, and tissue remodeling
Target & Disease MCP correctly resolves MET to c-Met/HGF receptor, a receptor tyrosine kinase activated by hepatocyte growth factor. Its signaling recruits PI3K, PLCG1, SRC, GRB2, STAT3, and GAB1, driving RAS-ERK, PI3K-AKT, and PLCgamma-PKC pathways that connect proliferation, scattering, morphogenesis, survival, wound repair, and tumor invasion.
Validation is substantial across oncology resistance settings
The MCP workflow retrieved 382 direct drug records, 271 development records, and 458 disease associations. Clinical Trials MCP returned 1,276 registered trial records. This supports MET as a validated but competitive target, especially where MET amplification, exon 14 skipping, or bypass resistance can guide patient selection.
Competition reflects both direct MET and multi-kinase strategies
Recent trial records include briitinib plus PLB1004 in EGFR-mutant NSCLC with MET abnormalities, zanzalintinib plus pembrolizumab in renal-cell carcinoma, and zanzalintinib in adenoid cystic carcinoma. The landscape spans selective MET biology, resistance combinations, and broader kinase/immunotherapy combinations.
IP and strategy view
MET IP strategy should emphasize mutation- or amplification-defined claims, CNS or safety differentiation, combination regimens after EGFR-TKI resistance, and biomarker-guided trial designs.
Clinical Validation and Competitive Landscape
Clinical Trials MCP returned 1276 registered trial records connected to MET. The sample below is used as a directional competitive readout rather than a full regulatory review.
| Trial | Phase | Status |
|---|---|---|
| Briitinib plus PLB1004 in EGFR-mutant NSCLC with MET abnormalities | Phase 2 | Completed |
| Zanzalintinib plus pembrolizumab in resectable clear-cell renal-cell carcinoma | Phase 2 | Not yet recruiting |
| Zanzalintinib in relapsed or metastatic adenoid cystic carcinoma | Phase 2 | Not yet recruiting |
R&D Strategy Recommendation
Use MET where the biomarker story is explicit. The best development path is not broad MET inhibition, but a patient-selection strategy tied to MET exon 14, amplification, resistance biology, or rational immuno-oncology combinations.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
